Novonorm pills 2mg №30

NovoNorm / NovoNorm

Composition and release form

NovoNorm - tablets:

1 pill contains repaglinide 0.5, 1 and 2 mg; in packing of 30 and 90 pieces.

pharmachologic effect

NovoNorm has a hypoglycemic effect.

Indications

Type 2 diabetes mellitus with the ineffectiveness of diet and exercise. In patients with type 2 diabetes, repaglinide can also be used in combination with Metformin in cases where satisfactory glycemia control cannot be achieved using repaglinide monotherapy or metformin.

Contraindications

known hypersensitivity to repaglinide or to any of the components NovoNorm; type 1 diabetes; diabetic ketoacidosis; diabetic precoma and coma; infectious diseases, major surgical interventions and other conditions requiring insulin therapy; pregnancy and breastfeeding. Clinical studies in patients in no younger than 18 years old and older than 75 years old.

Side effects

The most frequent side effects are changes in blood glucose, i.e. hypoglycemia. The frequency of such reactions depends, as with the use of any type of therapy for diabetes mellitus, on individual factors, such as dietary habits, the dosage of the drug, physical exertion and stress. Hypersensitivity reactions, such as itching, rash,hives. Very rarely, generalized hypersensitivity reactions or immunological reactions, such as vasculitis, can occur. Hypoglycemia. As with the use of other hypoglycemic agents, hypoglycemia may develop when repaglinide is used. Hypoglycemia can manifest itself with the following symptoms: anxiety, dizziness, sweating, tremor, hunger, difficulty concentrating. These reactions in most cases are not heavy and can be eliminated by carbohydrate intake. In severe reactions (hypoglycemia with loss of consciousness, hypoglycemic coma), medical care may be required, in particular, intravenous administration of dextrose (glucose). However, such reactions are extremely rare, it is impossible to determine their frequency, based on the available data. The risk of hypoglycemia may increase with the interaction of repaglinide with other drugs (see the Interaction section). Changes in the level of glucose in the blood can lead to visual disorders, especially at the initial stage of therapy with hypoglycemic drugs. However, these changes are usually transient in nature. Abdominal pain, diarrhea, nausea, vomiting and constipation may occur. However, the frequency and severity of these symptoms did not differ from those in the use of other oral medications that stimulate insulin secretion. Violations of the liver - in very rare cases, severe violations of liver function were reported, but a causal relationship with repaglinide was not established.

Dosage and administration

NovoNorm take inside.Assigned as a supplement to diet and exercise to reduce blood glucose levels; taking the drug should be timed to meals.

The recommended initial single dose NovoNorm before the main meal is 0.5 mg. Dose adjustment is carried out 1 time per week or 1 time in 2 weeks (while focusing on the level of glucose in the blood as an indicator of response to therapy). If the patient moves from taking another oral hypoglycemic agent to NovoNorm treatment, then the recommended initial dose before each main meal should be 1 mg.

special instructions

Repaglinide is not recommended to be administered simultaneously with gemfibrozil. However, if such a combination therapy is necessary, it should be carefully monitored for blood glucose, as it may be necessary to reduce the dose of repaglinide.

Storage conditions and shelf life

Store in a cool and dark place, protected from light and moisture, at a temperature not higher than 20 ° C. Shelf life - 4 years.